MLN02: Phase II data

In a double-blind, placebo-controlled Phase II trial in 181 patients, clinical remission at 6 weeks was achieved by 33% and 32% of patients receiving 0.5 and 2 mg/kg IV MLN02, respectively, vs. 14% on...